Trials / Completed
CompletedNCT04725240
Open-Label Study of Setmelanotide in Hypothalamic Obesity
A Phase 2, Open-Label 20-Week Study to Evaluate the Safety and Efficacy of Setmelanotide in Subjects With Hypothalamic Obesity
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Rhythm Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 6 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
Open-label, single-arm study designed to evaluate the body weight response to setmelanotide administered subcutaneously (SC) daily in participants with hypothalamic obesity (HO).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Setmelanotide | Setmelanotide for SC injection |
Timeline
- Start date
- 2021-06-07
- Primary completion
- 2022-06-28
- Completion
- 2022-06-28
- First posted
- 2021-01-26
- Last updated
- 2025-02-07
- Results posted
- 2023-09-21
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04725240. Inclusion in this directory is not an endorsement.